Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prazosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1B known ✓ | P35368 | 7/20 | 0.96 |
| ▸ | ADRA1A known ✓ | P35348 | 6/20 | 0.96 |
| ▸ | ADRA1D known ✓ | P25100 | 4/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.96 |
| ▸ | GLA | P06280 | 4/20 | 0.96 |
| ▸ | GAA | P10253 | 4/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.96 |
| ▸ | MAPT | P10636 | 3/20 | 0.96 |
| ▸ | HPGD | P15428 | 3/20 | 0.96 |
| ▸ | RAB9A | P51151 | 3/20 | 0.96 |
| ▸ | LMNA | P02545 | 2/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.96 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.96 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.96 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.96 |
| ▸ | NPC1 | O15118 | 2/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.96 |
| ▸ | MEN1 | O00255 | 1/20 | 0.96 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prazosin SCHEMBL26524 | 0.98 | ADRA1B (1.00) | ADRA1BADRA1AKDM4EGLAGAA | |
| Prazosin SCHEMBL29376126 | 0.98 | ADRA1B (1.00) | ADRA1BADRA1AKDM4EGLAGAA | |
| Prazosin SCHEMBL611396 | 0.97 | ADRA1B (1.00) | ADRA1BADRA1AKDM4EGLAGAA | |
| Prazosin SCHEMBL29908896 | 0.97 | ADRA1B (1.00) | ADRA1BADRA1AKDM4EGLAGAA | |
| Prazosin SCHEMBL41257 | 0.97 | ADRA1B (1.00) | ADRA1BADRA1AKDM4EGLAGAA | |
| Prazosin SCHEMBL1172954 | 0.97 | ADRA1B (1.00) | ADRA1BADRA1AKDM4EGLAGAA | |
| Prazosin SCHEMBL9663302 | 0.96 | KDM4E (1.00) | ADRA1BADRA1AKDM4EGLAGAA | |
| Prazosin SCHEMBL11656542 | 0.96 | KDM4E (1.00) | ADRA1BADRA1AKDM4EGLAGAA | |
| Prazosin SCHEMBL29157754 | 0.95 | ADRA1A (0.94) | ADRA1BADRA1AKDM4EGLAGAA | |
| SCHEMBL7797445 | 0.94 | ADRA1B (0.93) | ADRA1BADRA1AKDM4EGLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3343 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025131019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-06-26 | — | — | WO | claimed |
| CN-119234815-A | Application of prazosin hydrochloride as strigolactone inhibitor | 湖南农业大学 | 2025-01-03 | — | — | CN | claimed |
| US-20240252528-A1 | Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2024-08-01 | — | — | US | claimed |
| CN-118169271-A | Method for detecting alpha-adrenergic receptor blocker, SSRI and 5-ARIs and application thereof | 巴中市产品质量检验检测中心 | 2024-06-11 | — | — | CN | claimed |
| EP-3737676-B1 | ACETAL COMPOUNDS AND THERAPEUTIC USES THEREOF | LIGAND PHARM INC (US) | 2024-03-06 | — | — | EP | claimed |
| EP-4259279-A1 | METHODS OF TREATING METABOLIC DISORDERS AND CARDIOVASCULAR DISEASE WITH INHIBIN SUBUNIT BETA E (INHBE) INHIBITORS | REGENERON PHARMACEUTICALS, INC. (US) | 2023-10-18 | — | — | EP | claimed |
| CN-116794183-A | Qualitative and quantitative determination method for 25 chemical drugs possibly added in auxiliary antihypertensive health food and/or Chinese patent medicine | 山西省检验检测中心(山西省标准计量技术研究院) | 2023-09-22 | — | — | CN | claimed |
| US-20230017661-A1 | COMPOSITIONS AND MODULAR NANO- AND MICROPARTICLES FOR THE DELIVERY OF VARIOUS AGENTS AND USE THEREOF | VERI NANO INC. (US) | 2023-01-19 | — | — | US | claimed |
| US-20220313726-A1 | Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2022-10-06 | — | — | US | claimed |
| WO-2022132666-A1 | METHODS OF TREATING METABOLIC DISORDERS AND CARDIOVASCULAR DISEASE WITH INHIBIN SUBUNIT BETA E (INHBE) INHIBITORS | REGENERON PHARMACEUTICALS, INC. (US) | 2022-06-23 | — | — | WO | claimed |
| EP-0222575-B1 | PRAZOSIN-PIRBUTEROL COMBINATION FOR BRONCHODILATION | PFIZER INC. (US) | 1990-12-27 | — | — | EP | claimed |
| US-4873330-A | AZEOTROPIC DISTILLATION OF HYDRATE WITH SELECTED ORGANIC SOLVENTS | ORION-YHTYMA OY (FI) | 1989-10-10 | — | — | US | claimed |
| US-4739055-A | HYPOTENSIVE AGENTS | ORION-YHTYMA OY (FI) | 1988-04-19 | — | — | US | claimed |
| EP-0222575-A1 | Prazosin-pirbuterol combination for bronchodilation | PFIZER INC. (US) | 1987-05-20 | — | — | EP | claimed |
| US-4601897-A | Prazosin-pirbuterol combination for bronchodilation | PFIZER INC. (US) | 1986-07-22 | — | — | US | claimed |
| EP-0126684-A2 | Drug delivery system utilizing thermosetting gels | MERCK & CO. INC. (US) | 1984-11-28 | — | — | EP | claimed |
| US-4478822-A | Drug delivery system utilizing thermosetting gels | MERCK & CO., INC. (US) | 1984-10-23 | — | — | US | claimed |
| US-4474752-A | DIAMINE MODIFIED POLYOXYETHYLENE-POLYOXYPROPYLENE COPOLYMER | MERCK & CO., INC. (US) | 1984-10-02 | — | — | US | claimed |
| US-4472380-A | CARBOXYALKYL DIPEPTIDE DERIVATIVES | MERCK & CO., INC. (US) | 1984-09-18 | — | — | US | claimed |
| US-4361564-A | Renoprotective treatments employing vasodilator compounds | EDWARDS K DAVID G | 1982-11-30 | — | — | US | claimed |